Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions essential for maintaining intracellular tonicity, transmembrane potential, and nerve impulse transmission. Dextrose 5% provides a source of calories and may improve serum osmolality. Sodium chloride 0.9% supplies sodium and chloride ions to maintain extracellular fluid volume and electrolyte balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion: 10-20 mEq/hour, not to exceed 40 mEq/hour or 200 mEq/day. Maximum concentration: 80 mEq/L via peripheral line, 200 mEq/L via central line. Rate dependent on serum potassium and clinical condition.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Not applicable as potassium is an endogenous electrolyte; distribution and elimination follow first-order kinetics with a rapid redistribution phase (t1/2 α ~15 min) and a slower terminal phase (t1/2 β ~6-8 h) reflecting equilibration with total body stores.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal (approximately 90% as potassium ion); minimal biliary/fecal elimination (<5% collectively).
Category C
Category A/B
Electrolyte
Electrolyte